<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357717</url>
  </required_header>
  <id_info>
    <org_study_id>ECT2018-001</org_study_id>
    <nct_id>NCT04357717</nct_id>
  </id_info>
  <brief_title>ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting</brief_title>
  <official_title>Clinical Evaluation of ExoDxâ„¢ Prostate (IntelliScore) in Men With Prior Negative Prostate Biopsy Presenting for a Repeat Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exosome Diagnostics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exosome Diagnostics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to confirm the performance of the ExoDx Prostate test in prior negative&#xD;
      biopsy patients now presenting for a repeat prostate biopsy.&#xD;
&#xD;
      Note: ExoDx Prostate test results are collected for correlation to biopsy results and are not&#xD;
      disclosed to the physician or study subject.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Endpoint:&#xD;
&#xD;
      Evaluate the correlation of the ExoDx Prostate test results with the outcome of prostate&#xD;
      biopsies in a prior negative repeat biopsy patient cohort.&#xD;
&#xD;
      Secondary Endpoints (exploratory):&#xD;
&#xD;
        1. Evaluate the clinical performance of the ExoDx Prostate test at the cut-point of 15.6&#xD;
           defined for the initial biopsy patient cohort.&#xD;
&#xD;
        2. Associate ExoDx Prostate test results with other ancillary studies including the use of&#xD;
           radiographic imaging (e.g. multiparametric MRI).&#xD;
&#xD;
        3. Evaluate the correlation of ExoDx Prostate as a function of risk. It is known that a&#xD;
           higher ExoDx Prostate score correlates to a higher risk of finding prostate cancer,&#xD;
           including HGPC, upon biopsy.&#xD;
&#xD;
        4. Evaluate ExoDx Prostate with and without inclusion of standard of care parameters such&#xD;
           as PSA, ethnicity, DRE, age and family history.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of the ExoDx Prostate test results with the outcome of prostate biopsies in a prior negative repeat biopsy patient cohort.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ExoDx Prostate</intervention_name>
    <description>Urine-based biomarker tool to support decision to biopsy in patients with PSA between 2-10ng/ml</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men, aged 50yrs or older with an elevated PSA between 2-10ng/ml and at least one prior&#xD;
        negative prostate biopsy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  50+ years of age&#xD;
&#xD;
          -  Clinical suspicion for prostate cancer&#xD;
&#xD;
          -  Elevated Prostate-specific Antigen between 2.0-10 ng/ mL&#xD;
&#xD;
          -  At least one (1) prior negative prostate biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of medications or hormones that are known to affect serum PSA levels within 3-6&#xD;
             months of study enrollment including 5-alpha-reductase inhibitors used in the&#xD;
             treatment of an enlarged prostate gland (benign prostatic hyperplasia). Drugs in this&#xD;
             class are finasteride (Proscar, Propecia) and dutasteride (Avodart).&#xD;
&#xD;
          -  Clinical symptoms of urinary tract infection (including prostatitis) at the time of&#xD;
             enrollment.&#xD;
&#xD;
          -  History of prostate cancer.&#xD;
&#xD;
          -  History of invasive treatments for benign prostatic hypertrophy (BPH) or lower urinary&#xD;
             track symptoms within 6 months of study enrollment.&#xD;
&#xD;
          -  No known hepatitis status (all types) and/or HIV documented in patient's medical&#xD;
             record.&#xD;
&#xD;
          -  Patients with history of concurrent renal/bladder tumors.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sonia Kumar, PhD</last_name>
    <phone>6175880500</phone>
    <email>Sonia.Kumar@bio-techne.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Somers</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Jersey Urology</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Pilallis</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>exosome</keyword>
  <keyword>ExoDx Prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

